Thrivent Financial for Lutherans Buys 119,760 Shares of Avanos Medical, Inc. $AVNS

Thrivent Financial for Lutherans boosted its position in Avanos Medical, Inc. (NYSE:AVNS) by 352.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 153,764 shares of the company’s stock after purchasing an additional 119,760 shares during the period. Thrivent Financial for Lutherans’ holdings in Avanos Medical were worth $1,778,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Versant Capital Management Inc raised its stake in shares of Avanos Medical by 49.7% in the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock valued at $31,000 after buying an additional 894 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Avanos Medical by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after acquiring an additional 1,121 shares during the last quarter. Federated Hermes Inc. increased its holdings in Avanos Medical by 6.9% in the 3rd quarter. Federated Hermes Inc. now owns 25,083 shares of the company’s stock worth $290,000 after acquiring an additional 1,612 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Avanos Medical by 969.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after acquiring an additional 2,307 shares during the period. Finally, Sio Capital Management LLC lifted its holdings in Avanos Medical by 1.0% during the second quarter. Sio Capital Management LLC now owns 288,849 shares of the company’s stock valued at $3,536,000 after purchasing an additional 2,860 shares during the last quarter. 95.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AVNS has been the subject of several recent research reports. Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce”.

Avanos Medical Stock Performance

NYSE AVNS opened at $15.13 on Thursday. The company’s 50 day simple moving average is $12.29 and its two-hundred day simple moving average is $11.80. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36. Avanos Medical, Inc. has a 1 year low of $9.30 and a 1 year high of $16.75. The stock has a market capitalization of $702.38 million, a PE ratio of -1.48 and a beta of 1.09.

Insider Activity

In related news, SVP Kerr Holbrook sold 15,000 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $11.00, for a total value of $165,000.00. Following the sale, the senior vice president owned 83,860 shares in the company, valued at approximately $922,460. This trade represents a 15.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.64% of the company’s stock.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.